Le coût du cancer du poumon

The cost of care of lung cancer has increased exponentially in recent years, with the rise of targeted cancer therapies. Health spending represents more than 10% of Gross Domestic Product for European countries. Medical and financial resources need to be closely examined in this period of financial crisis. More individual and consequently expensive care has the consequence that medicine needs to adapt to reach a sustainable financial model. Medico-economic evaluations are essential in order to find the best balance between cost and efficiency. The various solutions to limit spending must be discussed, in order to ensure equal access to health care and to limit the impact on the macroeconomy.